Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

81.15EUR
24 May 2018
Change (% chg)

€0.45 (+0.56%)
Prev Close
€80.70
Open
€81.40
Day's High
€81.45
Day's Low
€80.95
Volume
2,905
Avg. Vol
94,355
52-wk High
€82.70
52-wk Low
€65.05

Chart for

About

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease,... (more)

Overall

Beta: 0.42
Market Cap(Mil.): €4,515.02
Shares Outstanding(Mil.): 55.95
Dividend: 1.80
Yield (%): 1.05

Financials

  DIAS.MI Industry Sector
P/E (TTM): 30.65 39.03 32.90
EPS (TTM): 2.63 -- --
ROI: -- 14.34 12.74
ROE: -- 17.21 14.64

BRIEF-Diasorin Receives FDA Clearance For Liaison Brahms Percent II Gen Assay For Sepsis

* RECEIVES FDA CLEARANCE FOR LIAISON BRAHMS PERCENT II GEN ASSAY TO DETECT SEVERE BACTERIAL INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 05 2018

BRIEF-DiaSorin Earns FDA Clearance Extending Sample Claims For HSV 1 & 2 Test

* EARNS FDA CLEARANCE EXTENDING SAMPLE CLAIMS FOR SIMPLEXA HSV 1 & 2 DIRECT MOLECULAR TEST

Mar 28 2018

BRIEF-DiaSorin FY Net Profit Up At EUR 139.9 Mln

* FY REVENUE EUR 637.5 MILLION VERSUS EUR 569.3 MILLION YEAR AGO

Mar 07 2018

BRIEF-DiaSorin Sees Tax Benefit In 2015-2017 Of 16-18 Mln Euros From Patent Box

* SIGNS AGREEMENT WITH TAX OFFICE REGARDING PATENT BOX TAX REGIME

Jan 30 2018

BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection

* SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​

Jan 08 2018

BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis

* ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS

Jan 08 2018

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 12 2017

Earnings vs. Estimates